![Immunologists seek ways to make TIL in solid tumors as effective as CAR T in blood cancers](https://cdn.cancerletter.com/media/2018/07/immuno-man-web2.jpg)
![Immunologists seek ways to make TIL in solid tumors as effective as CAR T in blood cancers](https://cdn.cancerletter.com/media/2018/07/immuno-man-web2.jpg)
Cover Story
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Lei Zheng named executive director of Mays Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”